estsin lyzynat | L-lysine escinate ampoules, 1 mg / ml, 5 ml, 10 pcs.
Special Price
$48.50
Regular Price
$57.00
In stock
SKU
BID470742
Release form
Concentrate for solution for intravenous administration of 1 mg / ml.
Concentrate for solution for intravenous administration of 1 mg / ml.
Release form
Concentrate for solution for intravenous administration of 1 mg / ml.
Packing
10 ampoules.
The pharmacological action of
L-lysine escinate® reduces the activity of lysosomal hydrolases, which prevents the splitting of mucopolysaccharides in the walls of the capillaries and in the connective tissue that surrounds them, and thus normalizes increased vascular tissue permeability and has an antiexudative (decongestant) and analgesic effect.
The drug increases vascular tone, has a moderate hypoglycemic effect.
Indications
Post-traumatic and postoperative edema of soft tissues of various localization.
Edema of the brain or spinal cord of traumatic or postoperative origin.
Disturbances of peripheral venous circulation, accompanied by edema.
Contraindications
Hypersensitivity to L-lysine escinate and / or other components of the drug.
Severe renal impairment.
Severe impairment of liver function.
Bleeding.
Children under 18 years old.
Pregnancy.
Breastfeeding period.
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation.
Special instructions
In some patients with hepatocholecystitis, a short-term increase in the activity of transaminases and bilirubin (direct fraction) is possible when prescribing the drug, which does not pose a threat to patients and does not require discontinuation of the drug.
Composition
Active ingredient:
L-lysine escinate, in terms of 100% substance - 1.0 mg.
Excipients:
ethanol (ethyl alcohol) 96% 200.0 mg,
propylene glycol 200.0 mg,
water for injection up to 1 ml.
Dosage and administration
The drug is administered strictly intravenously slowly in a stream or drip (intra-arterial administration is not allowed!) in a daily dose of 5-10 ml. Intravenous drip is recommended.
When preparing an infusion solution of L-lysine, escinate® is diluted in 50-100 ml of a 0.9% sodium chloride solution. If necessary, intravenous jet administration of L-lysine, escinate® is diluted in 10-15 ml of 0.9% sodium chloride solution. Without preliminary dilution, the drug is not used.
In conditions that threaten the patient’s life (traumatic brain injury, postoperative edema of the brain and spinal cord with edema-swelling, large swelling due to extensive soft tissue injuries), the daily dose is increased to 20 ml, divided into 2 doses. The duration of treatment is from 2 to 8 days, depending on the condition of the patient and the effectiveness of therapy.
While taking the drug should refrain from driving vehicles and other mechanisms.
Side effects of
With individual hypersensitivity to escin in individual patients, the following are possible:
Allergic reactions: skin rash (papular, petechial, erythematous), itching, flushing of the face, lips, fever, urticaria, in isolated cases - Quincke's edema, anaphylactic shock
From the central and peripheral nervous system: headache, dizziness, tremor, in rare cases - ataxia, short-term loss of consciousness
From the liver and biliary system: increased activity of transaminases and bilirubin
From the side gastrointestinal tract: nausea, in isolated cases - vomiting, diarrhea
From the cardiovascular system: lowering blood pressure (hypotension), increased blood pressure (hypertension), tachycardia , Chest pain
of the respiratory system: isolated cases - the feeling of breathlessness, shortness of breath, bronchial obstruction, dry cough
Local reactions: burning along the vein when administered, phlebitis, pain in the arm
Other: general weakness, chills, fever.
If any of the side effects indicated in the instructions are aggravated, or you notice any other side effects not listed in the instructions, inform your doctor.
Drug Interactions
The drug should not be used concurrently with aminoglycosides because of the possibility of increasing their nephrotoxicity. In the case of the recent, prior administration of L-lysine escinate®, long-term therapy with anticoagulants or, if necessary, the simultaneous administration of L-lysine of escinate® and anticoagulants, it is necessary to adjust the dose of the latter under the control of the prothrombin index.
The binding of escin to plasma proteins is hindered by the simultaneous use of cephalosporin antibiotics, which can increase the concentration of free escin in the blood with the risk of side effects of the latter.
Overdose
Symptoms: fever, tachycardia, nausea, heartburn, epigastric pain.
Treatment: symptomatic therapy.
Storage Conditions
Store in a dark place at a temperature of 15 РC to 25 РC.
Keep out of the reach and sight of children.
Shelf life
2 years.
Deystvuyushtee substance
Эstsina lysinate
Dosage form
infusion solution
Prescribing
Prescribing
Adults prescribed by a doctor
Halychpharm, Ukraine
Concentrate for solution for intravenous administration of 1 mg / ml.
Packing
10 ampoules.
The pharmacological action of
L-lysine escinate® reduces the activity of lysosomal hydrolases, which prevents the splitting of mucopolysaccharides in the walls of the capillaries and in the connective tissue that surrounds them, and thus normalizes increased vascular tissue permeability and has an antiexudative (decongestant) and analgesic effect.
The drug increases vascular tone, has a moderate hypoglycemic effect.
Indications
Post-traumatic and postoperative edema of soft tissues of various localization.
Edema of the brain or spinal cord of traumatic or postoperative origin.
Disturbances of peripheral venous circulation, accompanied by edema.
Contraindications
Hypersensitivity to L-lysine escinate and / or other components of the drug.
Severe renal impairment.
Severe impairment of liver function.
Bleeding.
Children under 18 years old.
Pregnancy.
Breastfeeding period.
Use during pregnancy and lactation
Contraindicated in pregnancy and lactation.
Special instructions
In some patients with hepatocholecystitis, a short-term increase in the activity of transaminases and bilirubin (direct fraction) is possible when prescribing the drug, which does not pose a threat to patients and does not require discontinuation of the drug.
Composition
Active ingredient:
L-lysine escinate, in terms of 100% substance - 1.0 mg.
Excipients:
ethanol (ethyl alcohol) 96% 200.0 mg,
propylene glycol 200.0 mg,
water for injection up to 1 ml.
Dosage and administration
The drug is administered strictly intravenously slowly in a stream or drip (intra-arterial administration is not allowed!) in a daily dose of 5-10 ml. Intravenous drip is recommended.
When preparing an infusion solution of L-lysine, escinate® is diluted in 50-100 ml of a 0.9% sodium chloride solution. If necessary, intravenous jet administration of L-lysine, escinate® is diluted in 10-15 ml of 0.9% sodium chloride solution. Without preliminary dilution, the drug is not used.
In conditions that threaten the patient’s life (traumatic brain injury, postoperative edema of the brain and spinal cord with edema-swelling, large swelling due to extensive soft tissue injuries), the daily dose is increased to 20 ml, divided into 2 doses. The duration of treatment is from 2 to 8 days, depending on the condition of the patient and the effectiveness of therapy.
While taking the drug should refrain from driving vehicles and other mechanisms.
Side effects of
With individual hypersensitivity to escin in individual patients, the following are possible:
Allergic reactions: skin rash (papular, petechial, erythematous), itching, flushing of the face, lips, fever, urticaria, in isolated cases - Quincke's edema, anaphylactic shock
From the central and peripheral nervous system: headache, dizziness, tremor, in rare cases - ataxia, short-term loss of consciousness
From the liver and biliary system: increased activity of transaminases and bilirubin
From the side gastrointestinal tract: nausea, in isolated cases - vomiting, diarrhea
From the cardiovascular system: lowering blood pressure (hypotension), increased blood pressure (hypertension), tachycardia , Chest pain
of the respiratory system: isolated cases - the feeling of breathlessness, shortness of breath, bronchial obstruction, dry cough
Local reactions: burning along the vein when administered, phlebitis, pain in the arm
Other: general weakness, chills, fever.
If any of the side effects indicated in the instructions are aggravated, or you notice any other side effects not listed in the instructions, inform your doctor.
Drug Interactions
The drug should not be used concurrently with aminoglycosides because of the possibility of increasing their nephrotoxicity. In the case of the recent, prior administration of L-lysine escinate®, long-term therapy with anticoagulants or, if necessary, the simultaneous administration of L-lysine of escinate® and anticoagulants, it is necessary to adjust the dose of the latter under the control of the prothrombin index.
The binding of escin to plasma proteins is hindered by the simultaneous use of cephalosporin antibiotics, which can increase the concentration of free escin in the blood with the risk of side effects of the latter.
Overdose
Symptoms: fever, tachycardia, nausea, heartburn, epigastric pain.
Treatment: symptomatic therapy.
Storage Conditions
Store in a dark place at a temperature of 15 РC to 25 РC.
Keep out of the reach and sight of children.
Shelf life
2 years.
Deystvuyushtee substance
Эstsina lysinate
Dosage form
infusion solution
Prescribing
Prescribing
Adults prescribed by a doctor
Halychpharm, Ukraine
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review